2025 年第 10 期 第 20 卷

复方红豆杉胶囊联合长春瑞滨和顺铂方案治疗晚期非小细胞肺癌的效果及对肿瘤标志物和免疫功能的影

The effect of compound Taxus capsule combined with vinorelbine and cisplatin in the treatment of advanced non-small cell lung cancer and its influence on tumor markers and immune function

作者：李丽张云

英文作者：Li Li Zhang Yun

单位：中国人民解放军北部战区总医院呼吸与危重症医学科，沈阳110000

英文单位：Department of Respiratory and Critical Care Medicine General Hospital of Northern Theater Command of the Chinese People′s Liberation Army Shenyang 110000 China

关键词：非小细胞肺癌；长春瑞滨；顺铂；复方红豆杉胶囊；肿瘤标志物；免疫功能

英文关键词：Non-smallcelllungcancer;Vinorelbine;Cisplatin;CompoundTaxuscapsule;Tumormarkers;Immunefunction

• 摘要：

• 目的 探讨复方红豆杉胶囊联合长春瑞滨＋顺铂（NP）方案治疗晚期非小细胞肺癌（NSCLC）的效果及对肿瘤标志物和免疫功能的影响。方法 前瞻性选取中国人民解放军北部战区总医院2022年6月至2024年1月收治的晚期NSCLC患者104例，采用随机数字表法分为观察组和对照组，各52例。对照组予NP方案治疗，观察组在对照组基础上联合复方红豆杉胶囊治疗，2组均治疗6个疗程。比较2组临床疗效、肿瘤标志物、免疫功能、生活质量和安全性。结果 观察组客观缓解率和疾病控制率均高于对照组［38.5%（20/52）比19.2%（10/52）、78.8%（32/52）比40.4%（21/52）］（均P<0.05）。治疗后，观察组肿瘤标志物血清癌胚抗原、细胞角蛋白19片段抗原、鳞状上皮细胞癌抗原均低于治疗前，且观察组均低于对照组（均P<0.05）。治疗后，2组CD+3、CD+4水平及CD+4/CD+8比值均高于治疗前，且观察组均高于对照组，CD+8水平均低于治疗前，且观察组低于对照组（均P<0.05）。治疗后，观察组肺癌生存质量测定量表各项评分均高于对照组（均P<0.05）。2组不良反应发生率比较差异无统计学意义（P>0.05）。结论 复方红豆杉胶囊联合NP方案治疗晚期NSCLC的效果满意，可降低肿瘤标志物水平，提高患者免疫功能，改善患者生存质量。

• Objective To investigate the effect of compound Taxus capsule combined with vinorelbine+cisplatin (NP) regimen in the treatment of advanced non-small cell lung cancer (NSCLC) and its influence on tumor markers and immune function. Methods A total of 104 patients with advanced NSCLC admitted to Chinese People′s Liberation Army Northern Theater General Hospital from June 2022 to January 2024 were prospectively selected. According to the random number table method, they were divided into observation group and control group, with 52 cases in each group. The control group was treated with NP regimen, and the observation group was treated with compound Taxus capsule on the basis of the control group. Both groups were treated for 6 courses. The clinical efficacy, tumor markers, immune function, quality of life and safety were compared between the two groups. Results The objective  remission rate and disease control rate of the observation group were higher than those of the control group ［38.5% (20/52) vs 19.2% (10/52) and 78.8% (32/52) vs 40.4% (21/52)］(both P<0.05). After treatment, the serum carcinoembryonic antigen, cytokeratin 19 fragment antigen and squamous cell carcinoma antigen in the observation group were lower than those before treatment, and those in the observation group were lower than those in the control group (all P<0.05). After treatment, the levels of CD+3 and CD+4 and CD+4/CD+8 ratio in the two groups were higher than those before treatment, and those in the observation group were higher than those in the control group, and the CD+8 level was lower than that before treatment, and that in the observation group was lower than that in the control group (all P<0.05). After treatment, the scores of the lung cancer quality of life scale in the observation group were higher than those in the control group (all P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion The effect of compound Taxus capsule combined with NP regimen in the treatment of advanced NSCLC is satisfactory, which can reduce the level of tumor markers, improve the immune function of patients, and improve the quality of life of patients.